Chison Medical Technologies マネジメント

マネジメント基準チェック /24

Chison Medical Technologiesの CEO はRuoli Moで、 Aug2002年に任命され、の在任期間は 22.25年です。は、会社の株式の23.6%を直接所有しており、その価値はCN¥ 700.40M 。経営陣と取締役会の平均在任期間はそれぞれ14.7年と1.3年です。

主要情報

Ruoli Mo

最高経営責任者

CN¥780.4k

報酬総額

CEO給与比率	n/a
CEO在任期間	22.3yrs
CEOの所有権	23.6%
経営陣の平均在職期間	14.7yrs
取締役会の平均在任期間	1.3yrs

経営陣の近況

Recent updates

Chison Medical Technologies' (SHSE:688358) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 06

The Market Lifts Chison Medical Technologies Co., Ltd. (SHSE:688358) Shares 39% But It Can Do More

Oct 08

Capital Allocation Trends At Chison Medical Technologies (SHSE:688358) Aren't Ideal

Sep 27

Chison Medical Technologies' (SHSE:688358) Solid Earnings May Rest On Weak Foundations

Apr 25

Further Upside For Chison Medical Technologies Co., Ltd. (SHSE:688358) Shares Could Introduce Price Risks After 27% Bounce

Mar 04

CEO（最高経営責任者

Ruoli Mo (50 yo)

22.3yrs

在職期間

CN¥780,400

報酬

Ms. Ruoli Mo is General Manager of Chison Medical Technologies Co., Ltd. since August 2002 and also serves as its Director since August 2017 and also serves as its Chairman since August 2023.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ruoli Mo	GM & Chairman	22.3yrs	CN¥780.40k	23.6% CN¥ 700.4m
Feng Zhou	Deputy GM	7.3yrs	CN¥835.00k	データなし
Wang Hong	Chief Technology Officer	12.1yrs	CN¥1.49m	データなし
Zhang Yong	Director of R & D Center High-End Color Doppler Ultrasound	17.3yrs	CN¥1.04m	データなし

14.7yrs

平均在職期間

48.5yo

平均年齢

経験豊富な経営陣: 688358の経営陣は経験豊富で経験豊富です（平均在職期間は14.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ruoli Mo	GM & Chairman	7.3yrs	CN¥780.40k	23.6% CN¥ 700.4m
Feng Zhou	Deputy GM	7.3yrs	CN¥835.00k	データなし
Shouxi Li	Independent Director	1.3yrs	CN¥42.20k	データなし
Ancheng Song	Independent Director	1.3yrs	CN¥42.20k	データなし
Yaoxin Hu	Chairman of the Board of Supervisors	1.3yrs	CN¥77.90k	データなし
Dongliang Gong	Supervisor & Software Department Manager	1.3yrs	CN¥237.10k	データなし

1.3yrs

平均在職期間

48yo

平均年齢

経験豊富なボード: 688358の取締役会は経験豊富ではない ( 1.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Chison Medical Technologies マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chison Medical Technologies Co., Ltd., Annual General Meeting, May 10, 2024

Recent updates

Chison Medical Technologies' (SHSE:688358) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Third quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.26 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

The Market Lifts Chison Medical Technologies Co., Ltd. (SHSE:688358) Shares 39% But It Can Do More

New minor risk - Share price stability

Chison Medical Technologies Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Capital Allocation Trends At Chison Medical Technologies (SHSE:688358) Aren't Ideal

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.53 in 2Q 2023)

Chison Medical Technologies Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Chison Medical Technologies' (SHSE:688358) Solid Earnings May Rest On Weak Foundations

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.47 in 1Q 2023)

Chison Medical Technologies Co., Ltd., Annual General Meeting, May 10, 2024

Now 21% undervalued after recent price drop

Chison Medical Technologies Co., Ltd. to Report Q1, 2024 Results on Apr 19, 2024

Investor sentiment improves as stock rises 18%

Further Upside For Chison Medical Technologies Co., Ltd. (SHSE:688358) Shares Could Introduce Price Risks After 27% Bounce

Now 23% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 17%

Third quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.44 in 3Q 2022)

Chison Medical Technologies Co., Ltd. (SHSE:688358) commences an Equity Buyback for CNY 20 million worth of its shares, under the authorization approved on September 12, 2023.

Second quarter 2023 earnings released: EPS: CN¥0.53 (vs CN¥0.46 in 2Q 2022)

Chison Medical Technologies Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 31%

First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.22 in 1Q 2022)

Third quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.28 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.33 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.27 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.22 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.32 (vs CN¥1.70 in FY 2019)

New 90-day low: CN¥49.00

New 90-day low: CN¥54.52

New 90-day low - CN¥61.94

New 90-day low - CN¥67.90

Chison Medical Technologies Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24